This is the first recorded instance of a bovine using tools from her environment to relieve an itch—leaving scientists ...

Scribe expects to initiate a first-in-human hypercholesterolemia study in mid-2026 with STX-1150, its lead cardiometabolic assetSTX-1150 is designed to deliver durable therapeutic LDL-C lowering with ...

For the last few years, the narrative around Generative AI in science has largely focused on administrative efficiency – ...

Picture CRISPR-Cas9, a gene editing technology, as a GPS-guided scalpel: gRNA directs the Cas9 enzyme, a protein that cuts ...

A bacterial defense system called SPARDA employs kamikaze-like tactics to protect cells and could be useful in future ...

Infection with the pathogenic yeast fungus Candida auris (C. auris) can wreak havoc on the health of hospital patients and ...

A profound transformation is taking place in therapeutic discovery, development, and delivery.2026 will be a pivotal year for ...

Nick Edwards, PhD, CEO of Potato, has a “burning desire” to speed up scientific discovery. In an interview with GEN, he explained how Potato’s AI “scientist,” named Tater, recently replicated a main ...

Aurora Therapeutics has emerged from stealth with $16 million in funding from Menlo Ventures to expand the potential of gene ...

Machine learning models reveal that histone marks are predictive of gene expression across human cell types and highlight important nuances between natural control and the effects of CRISPR-Cas9-based ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated ...

Friday, Aurora Therapeutics debuted with $16 million in seed capital from Menlo Ventures. Its goal: To develop the industry’s ...